Low Tsu-Hui Hubert, Yeh David, Zhang Tina, Araslanova Rakhna, Hammond J Alex, Palma David, Read Nancy, Venkatesan Varagur, MacNeil S Danielle, Yoo John, Nichols Anthony, Fung Kevin
Department of Head and Neck Surgery, Chris O'Brien Lifehouse/Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Central Clinical School, University of Sydney, Camperdown, New South Wales, Australia.
Laryngoscope. 2017 Jun;127(6):1322-1327. doi: 10.1002/lary.26317. Epub 2016 Oct 25.
OBJECTIVES/HYPOTHESIS: Common endpoints in reporting the outcomes for early glottic cancer do not highlight the importance of organ preservation. We evaluated the treatment outcomes among patients with T1aN0 laryngeal cancer with laryngectomy-free disease-specific survival (LFS-DSS), which is defined as time to total laryngectomy or time to death from cancer cause, against all other endpoints.
Outcome research on an institutional database.
A retrospective review covered all consecutive patients from 2003 to 2013. Patients with T1a laryngeal squamous cell carcinoma (SCC) were offered the options of either radiation treatment (RT) or transoral laser microsurgery (TLM). Tumor control, survival outcomes, standard definition laryngectomy-free survival (LFS), and LFS-DSS were calculated.
There were 105 patients, of whom 53 were treated with TLM and 52 were treated with RT. There were 11 recurrences within the TLM group, of which four were successfully salvaged with repeated TLM and two were salvaged with RT. Among the four recurrences within the RT group, all four patients had salvage total laryngectomies. The 5-year overall survival for patients treated with TLM versus RT was 86% versus 85% (P = .887), disease-free survival was 69% versus 78% (P = .151), LFS was 65% versus 77% (P = .198), LFS-DSS was 100% versus 88% (P = .030), and ultimate locoregional control was 100% in both groups.
Patients with T1aN0 glottic SCC treated with RT or TLM have similar survival outcomes. Patients with T1a tumor treated with TLM have better organ preservation compared to RT, when measured with LFS-DSS.
目的/假设:报告早期声门癌治疗结果时常用的终点未突出器官保留的重要性。我们评估了T1aN0喉癌患者无喉切除术疾病特异性生存(LFS - DSS)的治疗结果,LFS - DSS定义为全喉切除术时间或因癌症死亡时间,并与所有其他终点进行比较。
对机构数据库进行结果研究。
回顾性分析2003年至2013年期间所有连续的患者。T1a喉鳞状细胞癌(SCC)患者可选择放射治疗(RT)或经口激光显微手术(TLM)。计算肿瘤控制、生存结果、标准定义的无喉切除术生存(LFS)和LFS - DSS。
共有105例患者,其中53例接受TLM治疗,52例接受RT治疗。TLM组有11例复发,其中4例通过重复TLM成功挽救,2例通过RT挽救。RT组的4例复发患者均接受了挽救性全喉切除术。接受TLM与RT治疗的患者5年总生存率分别为86%和85%(P = 0.887),无病生存率分别为69%和78%(P = 0.151),LFS分别为65%和77%(P = 0.198),LFS - DSS分别为100%和88%(P = 0.030),两组的最终局部区域控制率均为100%。
接受RT或TLM治疗的T1aN0声门SCC患者生存结果相似。与RT相比,用LFS - DSS衡量时,接受TLM治疗的T1a肿瘤患者器官保留情况更好。
4。《喉镜》,2017年,第127卷,第1322 - 1327页